Left Atrial Appendage Closure: A Single-Center Experience in a Population With a High Prevalence of End-Stage Renal Disease.

Background Left atrial appendage closure (LAAC) has emerged as an alternative approach for mitigating thrombotic risk in nonvalvular atrial fibrillation patients. However, existing registries often lack representation of the Hispanic population, motivating this study to elucidate the demographic, clinical, and procedural characteristics, specifically among Hispanic patients undergoing this procedure. Methods Adult patients who underwent percutaneous LAAC between June 2017 and July 2022 at a high-complexity hospital in Bogotá, COL, were included. Baseline and procedural characteristics are reported. For patients with available follow-up data, major bleeding, thromboembolic events, and cardiovascular mortality were assessed. A subgroup analysis was conducted for patients with end-stage renal disease on dialysis. Results We included 33 patients. Follow-up data were available for 27 patients, with a mean follow-up period of 12.4 months. The median age of the cohort was 70 years (SD 9), with 58% being women. The median CHADS2 and HAS-BLED scores were 3 points (IQR 2 to 4) and 4 points (IQR 3 to 4), respectively. The 90-day cardiovascular mortality rate was 3.7%, whereas cardioembolic episodes and major bleeding events were reported at rates of 10.8 and 14.4 per 100 patient years, respectively. The long-term outcomes of patients on dialysis were comparable to those of nondialysis patients. Conclusions Our study reinforces existing evidence supporting the safety of LAAC, particularly in a multimorbid patient population with elevated bleeding and thrombotic risks. In this high-risk cohort, LAAC emerges as a feasible alternative for reducing thromboembolic risk. Notably, patients on dialysis demonstrated comparable long-term outcomes, suggesting the procedure's viability in this subgroup as well.